IL320183A - 2-תחליף 3,4 a, 5, 7, 8, 8 a-hexahydro-4h-thiop yrano [4,3- djpyrimidin-4-ones לטיפול בפצעים - Google Patents

2-תחליף 3,4 a, 5, 7, 8, 8 a-hexahydro-4h-thiop yrano [4,3- djpyrimidin-4-ones לטיפול בפצעים

Info

Publication number
IL320183A
IL320183A IL320183A IL32018325A IL320183A IL 320183 A IL320183 A IL 320183A IL 320183 A IL320183 A IL 320183A IL 32018325 A IL32018325 A IL 32018325A IL 320183 A IL320183 A IL 320183A
Authority
IL
Israel
Prior art keywords
yrano
thiop
djpyrimidin
hexahydro
ones
Prior art date
Application number
IL320183A
Other languages
English (en)
Inventor
John Joseph Palsted Delgado
Daniel D Holsworth
Sarika Saraswati
Original Assignee
Eluciderm Inc
John Joseph Palsted Delgado
Daniel D Holsworth
Sarika Saraswati
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eluciderm Inc, John Joseph Palsted Delgado, Daniel D Holsworth, Sarika Saraswati filed Critical Eluciderm Inc
Publication of IL320183A publication Critical patent/IL320183A/he

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL320183A 2022-10-18 2023-10-18 2-תחליף 3,4 a, 5, 7, 8, 8 a-hexahydro-4h-thiop yrano [4,3- djpyrimidin-4-ones לטיפול בפצעים IL320183A (he)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263417257P 2022-10-18 2022-10-18
US202263418947P 2022-10-24 2022-10-24
US202263418956P 2022-10-24 2022-10-24
PCT/US2023/035442 WO2024086246A2 (en) 2022-10-18 2023-10-18 2-substituted 3,4 a, 5, 7, 8, 8 a-hexahydro-4h-thiop yrano [4,3- djpyrimidin-4-ones for wound treatment

Publications (1)

Publication Number Publication Date
IL320183A true IL320183A (he) 2025-06-01

Family

ID=88793232

Family Applications (1)

Application Number Title Priority Date Filing Date
IL320183A IL320183A (he) 2022-10-18 2023-10-18 2-תחליף 3,4 a, 5, 7, 8, 8 a-hexahydro-4h-thiop yrano [4,3- djpyrimidin-4-ones לטיפול בפצעים

Country Status (8)

Country Link
EP (1) EP4605084A2 (he)
JP (1) JP2025535316A (he)
KR (1) KR20250093525A (he)
CN (1) CN120500488A (he)
AU (1) AU2023365200A1 (he)
IL (1) IL320183A (he)
MX (1) MX2025004545A (he)
WO (1) WO2024086246A2 (he)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025194162A1 (en) * 2024-03-15 2025-09-18 Eluciderm Inc. Pharmaceutical compositions of wnt pathway inhibitors for wound treatment

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
KR890002631B1 (ko) 1984-10-04 1989-07-21 몬산토 캄파니 생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
WO1997001331A2 (en) 1995-06-27 1997-01-16 Takeda Chemical Industries, Ltd. Method of producing sustained-release preparation
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
ES2221019T3 (es) 1996-10-31 2004-12-16 Takeda Chemical Industries, Ltd. Preparacion de liberacion mantenida.
ZA9711385B (en) 1996-12-20 1999-06-18 Takeda Chemical Industries Ltd Method of producing a sustained-release preparation
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
WO2000042025A1 (en) * 1999-01-14 2000-07-20 Meiji Seika Kaisha, Ltd. Poly(adp-ribose) polymerase inhibitors consisting of pyrimidine derivatives
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
FI3691649T3 (fi) 2017-10-06 2023-01-13 Koostumukset ja menetelmät haavan hoitamista varten
EP4401737A1 (en) 2021-09-13 2024-07-24 Eluciderm Inc. Composition for use in a method for cartilage regeneration and regrowth following injury

Also Published As

Publication number Publication date
WO2024086246A8 (en) 2025-05-22
WO2024086246A2 (en) 2024-04-25
KR20250093525A (ko) 2025-06-24
MX2025004545A (es) 2025-06-02
WO2024086246A3 (en) 2024-05-30
JP2025535316A (ja) 2025-10-24
CN120500488A (zh) 2025-08-15
AU2023365200A1 (en) 2025-05-15
EP4605084A2 (en) 2025-08-27

Similar Documents

Publication Publication Date Title
GB201900859D0 (en) Robotic, mobile apparatus for treating a room, for example by disinfection
GB202309744D0 (en) New treatments for pain
GB201900867D0 (en) Robotic, mobile apparatus for treating a room, for example by disinfection
GB2609162B (en) A system for monitoring a patient
MX2025004545A (es) 3,4 a, 5, 7, 8, 8a-hexahidro-4h-tiopirano [4,3-d] pirimidin-4-onas 2-sustituidas para el tratamiento de heridas
CA3270995A1 (en) 2-substituted 3,4 a, 5, 7, 8, 8 a-hexahydro-4h-thiop yrano [4,3- djpyrimidin-4-ones for wound treatment
PL3988524T3 (pl) Sposób wytwarzania propano-1,2-diolu
GB201900868D0 (en) Robotic, mobile apparatus for treating a room, for example by disinfection
HUE061232T2 (hu) Eljárás 1,2-propándiol elõállítására
HUE060335T2 (hu) Eljárás 1,2-propándiol elõállítására
PL3988529T3 (pl) Sposób wytwarzania 1,2-propanodiolu
HUE073600T2 (hu) Eljárás 1,2-propándiol elõállítására
EP4029860A4 (en) METHOD FOR PRODUCING A 1,5-BENZOTHIAZEPIN COMPOUND
HK40130358A (en) 2-substituted 3,4 a, 5, 7, 8, 8 a-hexahydro-4h-thiop yrano [4,3- d]pyrimidin-4-ones for wound treatment
HUE073413T2 (hu) Eljárás 1,2-propándiol elõállítására
AU2022901690A0 (en) A nasal treatment for COVID
GB202107726D0 (en) Antimicrobial component for a wound dressing
GB202213972D0 (en) 5000%vv3davtripple4000x10,000xshohryakuvaizonevaivai137millioncirclexdot shohryakuvaivai13millioncirclexdotgagaligagaligaligaligaligaalishohryakuvaishohryakuv
GB202213971D0 (en) 5000%vv3davtripple4000x10,000xshohryakuvai137millioncirclexdotshohryakuvaizonevai shohryakuvaizonevaivai13millioncircleexdotgagaligagaligaligaligaligalishohry
GB202213970D0 (en) 5000%vv3davtripple4000x10,000xshohryakuvaixonevaivai137millioncirclexdotshohryakuvaizonevai Shohryakuvaizonevaivai13millioncirclexdotgagaligagaligalifaligalig
AU2021902236A0 (en) Wound treatment
AU2020902305A0 (en) Wound treatment
CA3287245A1 (en) Loop line for h2s treatment
AU2024242088A1 (en) Loop line for h2s treatment
GB202316077D0 (en) New treatments for pain